Alzheimer’s Disease and Frontal Temporal Dementia
Hallucinations in Alzheimer’s Still Have No Approved Treatment, and the Biggest Trial Program Just Slipped to 2027 (Medicaldaily)
Summary: Bristol Myers Squibb has pushed topline readouts for its three ADEPT trials of Cobenfy in Alzheimer’s disease psychosis to early 2027, a second delay after slower enrollment and relapse accrual. No drug is FDA-approved for this indication, leaving off-label antipsychotics with a boxed mortality warning as the only pharmacologic option. The delay does not signal failure—trials remain blinded—but it extends the period of uncertainty for families and clinicians. Open-label data and an interim analysis are expected later in 2026, with competitor programs from Acadia and MapLight also in early phases.
Why it matters: For the Alzheimer’s and FTD community, this delay prolongs the absence of any approved treatment for psychosis, a condition affecting up to half of patients, and keeps families reliant on off-label drugs with known mortality risks.
Context: The ADEPT program is the most advanced effort to repurpose Cobenfy, a muscarinic agonist approved for schizophrenia, for Alzheimer’s psychosis. The class boxed warning, in place since 2005, has never been lifted, and no antipsychotic has gained approval for this indication.
"Roughly a third to a half of people with Alzheimer’s disease develop psychosis at some point, meaning hallucinations, delusions, or both. There is no medication approved in the United States to treat it." — MEDICALDAILY
Commentary: The delay is a reminder that regulatory timelines in neuropsychiatry are fragile, but the slower relapse accrual in ADEPT-1 is a genuinely encouraging signal—if it reflects drug efficacy, not just chance. The open-label data due later this year will be scrutinized for safety signals in a frail population, but only the blinded readouts will settle the question. Meanwhile, the off-label status quo remains a clinical and ethical pressure point, and the FDA’s reanalysis of the boxed warning could shift practice before any new approval arrives.
Date: July 31, 2026 08:15 PM ET
URL: https://medicaldaily.com/alzheimers-psychosis-treatment-gap-adept-cobenfy-delay-2027-boxed-warning-476732
AI Sentiment Score: Positive (44%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Alzheimer’s blood tests are transforming how patients get diagnosed — here’s what to know (Livescience)
Summary: At the Alzheimer’s Association International Conference in London, researchers detailed the current state of FDA-approved blood tests for Alzheimer’s disease, which measure tau and amyloid proteins to detect early pathology. The tests, including Roche’s Elecsys pTau181 and Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, show high accuracy in trials but are not yet approved for primary care use in the U.S. A key finding: the more accurate pTau217 biomarker outperforms pTau181, and early data suggest it may work in cognitively unimpaired people, hinting at future preventive screening. However, experts caution against mass screening due to false-positive risks, and the tests remain adjuncts to confirmatory imaging or lumbar puncture.
Why it matters: For clinicians and patients navigating early Alzheimer’s diagnosis, these blood tests could replace invasive and costly confirmatory procedures, but their real-world performance—including a recall for false positives—underscores the gap between trial accuracy and clinical utility.
Context: The first disease-modifying antibodies (lecanemab, donanemab) only slow progression, making early detection critical. The FDA has approved two blood tests, but the NHS has rejected the drugs as too costly, highlighting divergent access and reimbursement landscapes.
"Alzheimer’s blood tests are transforming how patients get diagnosed — here’s what to know New tests for Alzheimer’s are helping people who are at risk of dementia get clarity on their condition,." — LIVESCIENCE
Commentary: The recall is the story: it exposes the chasm between trial-grade performance and real-world reliability, a pattern familiar in biomarker adoption. The push toward pTau217, with its 96.1% sensitivity and 94.7% specificity, suggests the field is converging on a more robust analyte, but the gray-zone results (up to 20% of patients) still force confirmatory testing, blunting the promised efficiency. The tantalizing prospect of presymptomatic screening remains a ‘next frontier’—but without published data on early treatment benefit, it risks outpacing therapeutic evidence. For now, these tests are a triage tool for specialists, not a home-run diagnostic, and the NHS’s cost-benefit calculus should give U.S. payers pause.
Date: July 31, 2026 05:00 AM ET
URL: https://www.livescience.com/health/alzheimers-dementia/alzheimers-blood-tests-are-transforming-how-patients-get-diagnosed-heres-what-to-know
AI Sentiment Score: Positive (44%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Lifestyle Changes May Slow Brain Aging Before Age 70 (Medscape)
Summary: A secondary analysis of the US POINTER trial presented at AAIC 2026 and published in JAMA Network Open found that a structured multidomain lifestyle intervention slowed increases in free water—a diffusion MRI marker of early white matter change—in adults aged 60 to under 70, but not in those 70 or older. Higher baseline free water predicted faster white matter hyperintensity progression and new cerebral microbleeds, suggesting it may flag vulnerable white matter before conventional MRI changes appear. The age interaction was prespecified but secondary, and the authors caution it does not mean older adults cannot benefit.
Why it matters: This is the first randomized trial evidence that lifestyle intervention timing may matter for measurable cerebrovascular health, not just cognition, and it positions free water as a potential early biomarker for patient selection and monitoring in dementia prevention trials.
Context: The US POINTER trial previously showed global cognitive benefits from a structured multidomain intervention versus self-guided education. This imaging substudy extends that by testing whether the benefit extends to white matter integrity, with a prespecified age split that aligns with the hypothesis that early intervention precedes irreversible vascular damage.
"“Multidomain lifestyle interventions may have a greater effect on white matter health when initiated earlier in older adulthood, before vascular and structural brain changes become more advanced,” lead investigator Pauline Maillard, PhD, Department of Neurology, UC Davis, told Medscape Medical News." — MEDSCAPE
Commentary: The free water finding is the sharpest signal here: it is the only MRI marker that moved with intervention, and it moved only in the under-70 group. That suggests the field’s standard endpoints—WMH volume, microbleeds—may be too coarse and too late to capture short-term lifestyle effects, which has direct implications for trial design and for how clinicians frame ‘when to start’ advice. The absence of effect on other markers also tempers enthusiasm: two years may simply be too short, or the intervention’s cognitive benefit may operate through non-vascular pathways. For now, the practical takeaway is that early sixties is the actionable window, and free water deserves validation as a surrogate endpoint in future prevention trials.
Date: July 29, 2026 08:00 PM ET
URL: https://medscape.com/viewarticle/lifestyle-intervention-may-slow-brain-aging-only-before-age-2026a1000pyf
AI Sentiment Score: Negative (62%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Post ID: e670d249